Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Consensus

—

Average target

$8.88

Implied upside

—

Analysts

—

Why Is ELUT Up Today?

Elutia Inc. shares gained 1.22% today on modest volume, with the uptick likely driven by investor interest ahead of the company's presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th. This upcoming speaking engagement represents a potential catalyst for visibility and investor outreach.

Bottom line: Elutia's modest gains today appear tied to anticipation of its H.C. Wainwright conference presentation, though the muted price action suggests limited immediate market enthusiasm. Investors should track the September 15th presentation for substantive announcements that could drive more meaningful price movement, while noting that current visibility into the company's fundamentals and growth drivers remains limited.